| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
J Thorac Cardiovasc Surg 1994;107:807-810
© 1994 Mosby, Inc.
CARDIOPULMONARY BYPASS, |
Vienna, Austria
From the Second Department of Surgery, University Hospital of Vienna, Vienna, Austria.
Received for publication Feb. 2, 1993. Accepted for publication July 30, 1993. Address for reprints; Michael Havel, MD, Second Department of Surgery, University of Vienna, Spitalglass 23, A-1090 Wien, Austria.
Abstract
Forty-five male patients with planned coronary artery bypass operation were randomized in a double blind fashion to receive either 6 million kallikrein inactivator units of aprotinin (high-dose group), 2 million kallikrein inactivator units of aprotinin (low-dose group), or placebo (control group). Postoperative bleeding was significantly decreased in both aprotinin groups in comparison to that in the control group (590 ml [290 to 1800 ml] high-dose group and 650 ml [280 to 1900 ml] low-dose group versus 920 ml (350 to 2700 ml) control group, p < 0.001). There was no difference between the two aprotinin groups. The need for postoperative blood transfusion was significantly lower in the aprotinin groups (1.46 [0 to 4] blood units high-dose group and 1.65 [0 to 5] blood units low-dose group versus 2.43 [0 to 7] blood units control group, p < 0.05). All patients underwent coronary angiography between the seventh and twelfth postoperative day. No difference was found among the three groups in patency of vein grafts—93.8% in the high-dose group, 94.5% in the low-dose groups, and 93.3% in the control group. Therefore, aprotinin significantly reduced postoperative bleeding and transfusion requirement after coronary artery bypass grafting without influencing early graft patency. (J THORAC CARDIOVASC SURG 1994;107:807-10)
This article has been cited by other articles:
|
|
 |
|
  X. Wang, Z. Zheng, H. Ao, S. Zhang, Y. Wang, H. Zhang, L. Li, and S. Hu A comparison before and after aprotinin was suspended in cardiac surgery: Different results in the real world from a single cardiac center in China J. Thorac. Cardiovasc. Surg., October 1, 2009; 138(4): 897 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Westaby Aprotinin: Twenty-five years of claim and counterclaim J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 487 - 491. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Mangano, Y. Miao, A. Vuylsteke, I. C. Tudor, R. Juneja, D. Filipescu, A. Hoeft, M. L. Fontes, Z. Hillel, E. Ott, et al. Mortality Associated With Aprotinin During 5 Years Following Coronary Artery Bypass Graft Surgery JAMA, February 7, 2007; 297(5): 471 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Body and C. D. Mazer Pro: Aprotinin Has a Good Efficacy and Safety Profile Relative to Other Alternatives for Prevention of Bleeding in Cardiac Surgery Anesth. Analg., December 1, 2006; 103(6): 1354 - 1359. [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Mangano, I. C. Tudor, C. Dietzel, and the Multicenter Study of Perioperative Ischemia Re The Risk Associated with Aprotinin in Cardiac Surgery N. Engl. J. Med., January 26, 2006; 354(4): 353 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W Sutton, M. A Duncan, V. A Chase, R. J Marcel, T. P Meyers, and R. E Wood Cardiopulmonary bypass and mitral valve replacement during pregnancy Perfusion, December 1, 2005; 20(6): 359 - 368. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Shander, D. Moskowitz, and T. S. Rijhwani The Safety and Efficacy of "Bloodless" Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, March 1, 2005; 9(1): 53 - 63. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Mahdy and N. R. Webster Perioperative systemic haemostatic agents Br. J. Anaesth., December 1, 2004; 93(6): 842 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kalkat, A. Levine, and J. Dunning Does use of aprotinin in coronary artery bypass graft surgery affect graft patency? Interactive CardioVascular and Thoracic Surgery, March 1, 2004; 3(1): 124 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Taggart, V. Djapardy, M. Naik, and A. Davies A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1087 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Karski and J. T. Balatbat Blood Conservation Strategies in Cardiac Surgery Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 175 - 188. [Abstract] [PDF]
|
|
|
|
 |
|
 R. C. Landis, G. Asimakopoulos, M. Poullis, D. O. Haskard, and K. M. Taylor The antithrombotic and antiinflammatory mechanisms of action of aprotinin Ann. Thorac. Surg., December 1, 2001; 72(6): 2169 - 2175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Landis, D. O. Haskard, and K. M. Taylor New antiinflammatory and platelet-preserving effects of aprotinin Ann. Thorac. Surg., November 1, 2001; 72(5): S1808 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Despotis, M. S. Avidan, and C. W. Hogue Jr Mechanisms and attenuation of hemostatic activation during extracorporeal circulation Ann. Thorac. Surg., November 1, 2001; 72(5): S1821 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Bidstrup, B. J. Hunt, S. Sheikh, R. N. Parratt, J. M. Bidstrup, and R. N. Sapsford Amelioration of the bleeding tendency of preoperative aspirin after aortocoronary bypass grafting Ann. Thorac. Surg., February 1, 2000; 69(2): 541 - 547. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. B. Berger, E. L. Alderman, A. Nadel, and H. V. Schaff Frequency of Early Occlusion and Stenosis in a Left Internal Mammary Artery to Left Anterior Descending Artery Bypass Graft After Surgery Through a Median Sternotomy on Conventional Bypass : Benchmark for Minimally Invasive Direct Coronary Artery Bypass Circulation, December 7, 1999; 100(23): 2353 - 2358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Eagle, R. A. Guyton, R. Davidoff, G. A. Ewy, J. Fonger, T. J. Gardner, J. P. Gott, H. C. Herrmann, R. A. Marlow, W. C. Nugent, et al. ACC/AHA guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/ American Heart Association task force on Practice Guidelines (Committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery) J. Am. Coll. Cardiol., October 1, 1999; 34(4): 1262 - 1347. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Munoz, N. J. O. Birkmeyer, J. D. Birkmeyer, G. T. O'Connor, and L. J. Dacey Is {epsilon}-Aminocaproic Acid as Effective as Aprotinin in Reducing Bleeding With Cardiac Surgery? : A Meta-Analysis Circulation, January 12, 1999; 99(1): 81 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Rich The efficacy and safety of aprotinin use in cardiac surgery Ann. Thorac. Surg., November 1, 1998; 66(90050): S6 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Misfeld, S. Dubbert, S. Eleftheriadis, H.-J. Siemens, T. Wagner, and H.-H. Sievers Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations Ann. Thorac. Surg., September 1, 1998; 66(3): 792 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Mannucci Hemostatic Drugs N. Engl. J. Med., July 23, 1998; 339(4): 245 - 253. [Full Text] [PDF]
|
|
|
|
|
|
B. Eberle, E. Mayer, G. Hafner, J. Heinermann, M. Dahm, W. Prellwitz, W. Dick, and H. Oelert High-Dose {epsilon}-Aminocaproic Acid Versus Aprotinin: Antifibrinolytic Efficacy in First-Time Coronary Operations Ann. Thorac. Surg., March 1, 1998; 65(3): 667 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Bidstrup Coronary Artery Bypass Graft Patency Seminars in Cardiothoracic and Vascular Anesthesia, November 1, 1997; 1(4): 282 - 287. [Abstract] [PDF]
|
|
|
|
|
|
N. Hayashida, T. Isomura, T. Sato, H. Maruyama, K. Kosuga, and S. Aoyagi EFFECTS OF MINIMAL-DOSE APROTININ ON CORONARY ARTERY BYPASS GRAFTING J. Thorac. Cardiovasc. Surg., August 1, 1997; 114(2): 261 - 269. [Abstract] [Full Text]
|
|
|
|
|
|
R. G. H. Speekenbrink, C. R. H. Wildevuur, A. Sturk, and L. Eijsman LOW-DOSE AND HIGH-DOSE APROTININ IMPROVE HEMOSTASIS IN CORONARY OPERATIONS J. Thorac. Cardiovasc. Surg., August 1, 1996; 112(2): 523 - 530. [Abstract] [Full Text]
|
|
|
|
|
|
J. H. Levy, R. Pifarre, H. V. Schaff, J. C. Horrow, R. Albus, B. Spiess, T. K. Rosengart, J. Murray, R. E. Clark, P. Smith, et al. A Multicenter, Double-Blind, Placebo-Controlled Trial of Aprotinin for Reducing Blood Loss and the Requirement for Donor-Blood Transfusion in Patients Undergoing Repeat Coronary Artery Bypass Grafting Circulation, October 15, 1995; 92(8): 2236 - 2244. [Abstract] [Full Text]
|
|
|
|
|
|
D. Green, J. Sanders, M. Eiken, C. A. Wong, J. Frederiksen, A. Joob, A. Palmer, A. Trowbridge, B. Woodruff, M. Moerch, et al. RECOMBINANT APROTININ IN CORONARY ARTERY BYPASS GRAFT OPERATIONS J. Thorac. Cardiovasc. Surg., October 1, 1995; 110(4): 963 - 970. [Abstract] [Full Text]
|
|
|
|
|
|
A. Wahba, A. Philip, M. Bauer, M. Kaiser, H. Aebert, and D. Birnbaum The blood saving potential of vortex versus roller pump with and without aprotinin Perfusion, September 1, 1995; 10(5): 333 - 341. [Abstract] [PDF]
|
|
|
|
|
|
B. Liu, L. Tengborn, G. Larson, L. O. G. Radberg, A. Belboul, L. Dernevik, and D. Roberts Half-Dose Aprotinin Preserves Hemostatic Function in Patients Undergoing Bypass Operations Ann. Thorac. Surg., June 1, 1995; 59(6): 1534 - 1540. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
